Dr. Eric P. Winer on Pathologic Complete Response and Disease Free Survival in Breast Cancer
Winer says patients who do well on carboplatin and show both a good pathologic complete response and good disease free survival may be patients who have refractory disease and are responding well to the treatment, while others may be patients who were bound to do well regardless.
Eric P. Winer, MD, chief of the Division of Women's Cancers, director of the Breast Oncology Program, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discusses the disconnect between a good pathologic complete response and disease free survival in patients with breast cancer.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
